Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency

  1. Jonathon W. Senefeld
  2. Stephen A. Klassen
  3. Shane K. Ford
  4. Chad C. Wiggins
  5. Bruce C. Bostrom
  6. Michael A. Thompson
  7. Sarah E. Baker
  8. Wayne T. Nicholson
  9. Patrick W. Johnson
  10. Rickey E. Carter
  11. Jeffrey P. Henderson
  12. William R. Hartman
  13. Liise-anne Pirofski
  14. R. Scott Wright
  15. DeLisa Fairweather
  16. Katelyn A. Bruno
  17. Nigel S. Paneth
  18. Arturo Casadevall
  19. Michael J. Joyner
2 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

<label>0</label>

Abstract

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.

Related articles

Related articles are currently not available for this article.